In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospitals and universities to manufacturers and investors — are rethinking their strategies amid global supply chain disruption.The conversation highlights both immediate operational responses and long-term structural shifts shaping a more resilient, agile, and locally grounded ecosystem, especially in light of U.S. tariffs.This episode is presented in partnership with <a href="https://www.element.com/" target="_blank" rel="ugc noopener noreferrer">Element Materials Technology</a>. Hosts<a href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank" rel="ugc noopener noreferrer">Jennifer Smith-Parker</a>, Director of Insights, BioSpace<a href="https://www.linkedin.com/in/lorielliskatz/" target="_blank" rel="ugc noopener noreferrer">Lori Ellis</a>, Head of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/jihyejanglee/" target="_blank" rel="ugc noopener noreferrer">Dr. Jihye Jang-Lee</a>, Director of Technical Services, Element Materials Technology<a href="https://www.linkedin.com/in/khanh-ngo-courtney-106a5232/" target="_blank" rel="ugc noopener noreferrer">Dr. Khanh Courtney</a>, Biologics Technical Strategy Manager, Element Materials Technology Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.